Your browser doesn't support javascript.
loading
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Pleyer, Lisa; Leisch, Michael; Kourakli, Alexandra; Padron, Eric; Maciejewski, Jaroslaw Pawel; Xicoy Cirici, Blanca; Kaivers, Jennifer; Ungerstedt, Johanna; Heibl, Sonja; Patiou, Peristera; Hunter, Anthony Michael; Mora, Elvira; Geissler, Klaus; Dimou, Maria; Jimenez Lorenzo, Maria-José; Melchardt, Thomas; Egle, Alexander; Viniou, Athina-Nora; Patel, Bhumika Jayantibhai; Arnan, Montserrat; Valent, Peter; Roubakis, Christoforos; Bernal Del Castillo, Teresa; Galanopoulos, Athanasios; Calabuig Muñoz, Marisa; Bonadies, Nicolas; Medina de Almeida, Antonio; Cermak, Jaroslav; Jerez, Andrés; Montoro, Maria Julia; Cortés, Albert; Avendaño Pita, Alejandro; Lopez Andrade, Bernardo; Hellstroem-Lindberg, Eva; Germing, Ulrich; Sekeres, Mikkael Aaron; List, Alan Francis; Symeonidis, Argiris; Sanz, Guillermo Francisco; Larcher-Senn, Julian; Greil, Richard.
Afiliação
  • Pleyer L; Third Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials, Salzburg, Austria. Electronic address: dr.lisa.pleyer@gmail.com.
  • Leisch M; Third Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.
  • Kourakli A; Hematology Division, Department of Internal Medicine, University of Patras Medical School, Patras, Greece.
  • Padron E; Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Maciejewski JP; Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Xicoy Cirici B; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Kaivers J; Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
  • Ungerstedt J; Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institute, and Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Heibl S; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria.
  • Patiou P; Hematology Division, Department of Internal Medicine, University of Patras Medical School, Patras, Greece.
  • Hunter AM; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
  • Mora E; Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Geissler K; Fifth Medical Department, Hospital Hietzing, Vienna, Austria.
  • Dimou M; 141st Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
  • Jimenez Lorenzo MJ; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Melchardt T; Third Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.
  • Egle A; Third Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.
  • Viniou AN; 141st Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
  • Patel BJ; Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Arnan M; Institut Català d'Oncologia-Hospital Duran y Reynals, Hospitalet de Llobregat, Barcelona, Spain.
  • Valent P; Department of Internal Medicine, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
  • Roubakis C; Department of Hematology, G GENNIMATAS General Hospital, Athens, Greece.
  • Bernal Del Castillo T; Hospital Universitario Central Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, University Institute of Oncology of Asturias-Cajastur Social Programme, Oviedo, Spain.
  • Galanopoulos A; Department of Hematology, G GENNIMATAS General Hospital, Athens, Greece.
  • Calabuig Muñoz M; Hospital Clinico Universitario de Valencia, Valencia, Spain.
  • Bonadies N; Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Switzerland.
  • Medina de Almeida A; Hospital da Luz, Lisbon, Portugal; Centro de Investigação Interdisciplinar em Saúde, Universidade Católica Portuguesa de Lisboa, Lisbon, Portugal.
  • Cermak J; Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
  • Jerez A; Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB, Murcia, Spain.
  • Montoro MJ; Hematology Department, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Cortés A; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Avendaño Pita A; Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Lopez Andrade B; Hematology Department Hospital Universitario Son Espases, Palma Mallorca, Spain.
  • Hellstroem-Lindberg E; Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institute, and Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Germing U; Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
  • Sekeres MA; Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • List AF; Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Symeonidis A; Hematology Division, Department of Internal Medicine, University of Patras Medical School, Patras, Greece.
  • Sanz GF; Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Centro de Investigacion Biomedica en Red Cance, Instituto Carlos III, Madrid, Spain.
  • Larcher-Senn J; Assign Data Management and Biostatistics, Innsbruck, Austria.
  • Greil R; Third Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials, Salzburg, Austria.
Lancet Haematol ; 8(2): e135-e148, 2021 Feb.
Article em En | MEDLINE | ID: mdl-33513373

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielomonocítica Crônica / Antineoplásicos Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielomonocítica Crônica / Antineoplásicos Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article